Literature DB >> 23788237

Laboratory diagnosis of Clostridium difficile infections: there is light at the end of the colon.

Stephen M Brecher1, Susan M Novak-Weekley, Elisabeth Nagy.   

Abstract

Single molecular or multistep assays (glutamate dehydrogenase, toxin A/B, ± molecular) are recommended for the diagnosis of CDI in patients with clinically significant diarrhea. Rapid and accurate tests can improve resource allocations and improve patient care. Enzyme immunoassay (EIA) for toxins A/B is too insensitive for use as a stand-alone assay. This guideline will examine the use of molecular tests and multitest algorithms for the diagnosis of Clostridium difficile infection (CDI). These new tests, alone or in a multistep algorithm consisting of >1 assay, are more expensive than the older EIA assays; however, rapid and accurate testing can save money overall by initiating appropriate treatment and infection control protocols sooner and by possibly reducing length of hospital stay. We recommend testing only unformed stool in patients with clinically significant diarrhea by a molecular method or by a 2- to 3-step algorithm.

Entities:  

Keywords:  Brecher guidelines; Clostridium difficile; laboratory design of C. difficile

Mesh:

Year:  2013        PMID: 23788237     DOI: 10.1093/cid/cit424

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  29 in total

1.  Real-time cellular analysis coupled with a specimen enrichment accurately detects and quantifies Clostridium difficile toxins in stool.

Authors:  Bin Huang; Dazhi Jin; Jing Zhang; Janet Y Sun; Xiaobo Wang; Jeffrey Stiles; Xiao Xu; Mini Kamboj; N Esther Babady; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2014-01-22       Impact factor: 5.948

2.  Molecular test based on isothermal helicase-dependent amplification for detection of the Clostridium difficile toxin A gene.

Authors:  Catherine Eckert; Eleonore Holscher; Amandine Petit; Valérie Lalande; Frédéric Barbut
Journal:  J Clin Microbiol       Date:  2014-04-23       Impact factor: 5.948

3.  The Daniel K. Inouye College of Pharmacy Scripts: Updates on Clostridium difficile Infection: Advances in Laboratory Testing to Aid Diagnosis and Treatment.

Authors:  Louis Lteif
Journal:  Hawaii J Med Public Health       Date:  2017-02

4. 

Authors:  George Kim; Nemin Adam Zhu
Journal:  Can Fam Physician       Date:  2017-02       Impact factor: 3.275

5.  Community-acquired Clostridium difficile infection.

Authors:  George Kim; Nemin Adam Zhu
Journal:  Can Fam Physician       Date:  2017-02       Impact factor: 3.275

6.  Characteristics and Antibiotic Use Associated With Short-Term Risk of Clostridium difficile Infection Among Hospitalized Patients.

Authors:  Sol del Mar Aldrete; Matthew J Magee; Rachel J Friedman-Moraco; Austin W Chan; Grier G Banks; Eileen M Burd; Colleen S Kraft
Journal:  Am J Clin Pathol       Date:  2015-06       Impact factor: 2.493

Review 7.  Emerging technologies for the clinical microbiology laboratory.

Authors:  Blake W Buchan; Nathan A Ledeboer
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

8.  Lactobacillus probiotics in the prevention of diarrhea associated with Clostridium difficile: a systematic review and Bayesian hierarchical meta-analysis.

Authors:  Alison Sinclair; Xuanqian Xie; Lama Saab; Nandini Dendukuri
Journal:  CMAJ Open       Date:  2016-11-24

9.  Premarket evaluations of the IMDx C. difficile for Abbott m2000 Assay and the BD Max Cdiff Assay.

Authors:  K A Stellrecht; A A Espino; V P Maceira; S M Nattanmai; S A Butt; D Wroblewski; G E Hannett; K A Musser
Journal:  J Clin Microbiol       Date:  2014-02-19       Impact factor: 5.948

Review 10.  Epidemiology, Diagnosis, and Management of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease.

Authors:  Krishna Rao; Peter D R Higgins
Journal:  Inflamm Bowel Dis       Date:  2016-07       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.